NeuroSense Therapeutics (NRSN) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, including ALS, Alzheimer's, and Parkinson's disease.

• Lead candidate PrimeC is a novel oral fixed-dose combination of ciprofloxacin and celecoxib, targeting multiple ALS disease pathways.

• PrimeC has orphan drug designation from both FDA and EMA for ALS and SME status from EMA.

• Pipeline includes additional programs for Alzheimer's and Parkinson's, with a combined product strategy.

• Management team has extensive pharmaceutical and ALS research experience, with strong ties to patient advocacy groups.

Financial performance and metrics

• As of September 30, 2024, pro forma shareholders' equity was $4.3 million, with $344,000 in cash.

• Recent private placements and equity agreements raised approximately $5 million in December 2024 and $4.47 million in April 2024.

• Ongoing Standby Equity Purchase Agreement allows up to $30 million in additional equity sales over 36 months.

• Company has a history of recurring losses and expects to incur significant additional losses, raising substantial doubt about its ability to continue as a going concern.

Use of proceeds and capital allocation

• No proceeds from the resale of shares, warrants, or warrant shares by the selling shareholder; company will only receive proceeds if warrants are exercised for cash.

• If all warrants are exercised, gross proceeds would be approximately $4.4 million.

• Proceeds, if received, will be used to advance clinical development of PrimeC for ALS, support IND applications for Alzheimer's and Parkinson's, and for general corporate purposes.